All In Biotech

Drug Trial Radar · NCT07540442

A Phase III Study of MG-K10 in Adolescents With Moderate-to-Severe Atopic Dermatitis

Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MG-K10 (a Humanized Monoclonal Antibody Injection) in Adolescents With Moderate-to-Severe Atopic Dermatitis

Last checked: Nov 20, 2026Latest source record: Apr 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 180 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

180

Planned (sponsor's estimate)

Start

Apr 17, 2026

Primary completion

Jan 5, 2027

Study completion Nov 9, 2027

Sponsor

Sponsor type
Industry
First posted
Apr 20, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 12 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled, parallel group study to confirm the efficacy and safety of MG-K10 monotherapy in adolescents with moderate-to-severe atopic dermatitis (AD)

Conditions

  • Dermatitis, Atopic

Interventions

  • MG-K10 Injection (Humanized Monoclonal Antibody)Drug

    loading dose (SC) at Week 0, followed by a single dose Q2W through Week 52

  • Placebo for MG-K10Drug

    Initial loading dose (SC), then single dose Q2W through Week 52

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants achieving EASI-75 ( ≥75% reduction from baseline )Time frame: week 16
  2. Proportion of participants achieving IGA score of 0 (clear) or 1 (almost clear) with a ≥2-point reduction from baselineTime frame: week 16

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Hospital Of China Medical University

    Shenyang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.